Trials / Completed
CompletedNCT00143130
Pregabalin In Partial Seizures Extension Study
Pregabalin in Partial Seizures (PREPS) Extension Study: An 18-month Follow-on Open-label, International, Multicenter Add-on Therapy Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 227 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate long-term efficacy and safety of pregabalin (150 to 600mg/day) as adjunctive treatment in patients with partial seizures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | Pregabalin |
Timeline
- Start date
- 2005-04-01
- Completion
- 2007-09-01
- First posted
- 2005-09-02
- Last updated
- 2021-01-28
Locations
47 sites across 6 countries: Belgium, Finland, France, Poland, Portugal, Switzerland
Source: ClinicalTrials.gov record NCT00143130. Inclusion in this directory is not an endorsement.